These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25196375)

  • 41. Appropriate therapy for type 2 diabetes mellitus in view of pancreatic β-cell glucose toxicity: "the earlier, the better".
    Kaneto H; Matsuoka TA; Kimura T; Obata A; Shimoda M; Kamei S; Mune T; Kaku K
    J Diabetes; 2016 Mar; 8(2):183-9. PubMed ID: 26223490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study.
    Xu W; Li YB; Deng WP; Hao YT; Weng JP
    Chin Med J (Engl); 2009 Nov; 122(21):2554-9. PubMed ID: 19951569
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Managing older adults with diabetes.
    Hainer TA
    J Am Acad Nurse Pract; 2006 Jul; 18(7):309-17. PubMed ID: 16827836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Insulin Action Research and the Future of Diabetes Treatment: The 2017 Banting Medal for Scientific Achievement Lecture.
    Accili D
    Diabetes; 2018 Sep; 67(9):1701-1709. PubMed ID: 30135131
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glycemic variability in patients with early type 2 diabetes: the impact of improvement in β-cell function.
    Kramer CK; Choi H; Zinman B; Retnakaran R
    Diabetes Care; 2014 Apr; 37(4):1116-23. PubMed ID: 24550219
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Practical guidance to insulin management.
    Meneghini L; Artola S; Caputo S; Damci T; Dzida G; Kaiser M; Khunti K; Liebl A; Ligthelm R; Maran A; Orozco-Beltran D; Ross S; Yale JF
    Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S43-56. PubMed ID: 20394891
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Perspectives in type 2 diabetes: incorporating the latest insulin analogue strategies to achieve treatment success.
    Diabetes Obes Metab; 2009 Nov; 11 Suppl 5():iii-iv. PubMed ID: 19817775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence-based recommendations for insulin intensification strategies after basal insulin in type 2 diabetes.
    Ghosh S; Unnikrishnan AG; Saboo B; Kesavadev J; Aravind SR; Bajaj S; Rajput R; Seshadri K; Verma N; Gupta A; Makkar BM; Saikia M; Kale S; Damodaran S; Dengra A; Eashwar TKM; Maheshwari A; Pendsey S; Phatak SR; Sharma SK; Singh SK; Ramachandran A; Zargar AH; Joshi SR; Sadikot SM
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S507-S521. PubMed ID: 28433618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?
    van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S37-46. PubMed ID: 21864750
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Insulin therapy in type 2 diabetes: short-acting insulin analog has advantages].
    MMW Fortschr Med; 2006 Jun; 148(26):56-7. PubMed ID: 16875384
    [No Abstract]   [Full Text] [Related]  

  • 52. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus.
    Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1170-5. PubMed ID: 22563104
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Insulin therapy: as late as possible].
    Jacob S
    Dtsch Med Wochenschr; 2016 Apr; 141(8):579-80. PubMed ID: 27078250
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Criteria and guidelines for combined therapy of type 2 diabetes. 2004 consensus document].
    Goday Arno A; Franch Nadal J; Mata Cases M
    Med Clin (Barc); 2004 Jul; 123(5):187-97. PubMed ID: 15274798
    [No Abstract]   [Full Text] [Related]  

  • 57. The lean patient with type 2 diabetes: characteristics and therapy challenge.
    P B
    Int J Clin Pract Suppl; 2007 Jun; (153):3-9. PubMed ID: 17594388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Provisional intensive insulin therapy in non-insulin-dependent diabetes resistant to usual treatment].
    Bringer J; Galtier-Dereure F; Augustin-Pascalis I; Richard JL; Parer-Richard C; Mirouze J; Jaffiol C
    Journ Annu Diabetol Hotel Dieu; 1993; ():115-22. PubMed ID: 8331859
    [No Abstract]   [Full Text] [Related]  

  • 59. Our evolving understanding of getting to goal using insulin in type 2 diabetes.
    Leroith D
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2():9-19. PubMed ID: 18407030
    [No Abstract]   [Full Text] [Related]  

  • 60. Social insulin resistance: The forgotten frontier.
    Kalra S; Arora V; Verma M; Aggarwal S
    J Pak Med Assoc; 2020 Oct; 70(10):1860-1861. PubMed ID: 33159771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.